00:01 We’ve heard about many different cytokines and it is very clear that they are crucially important in playing many, many different roles in controlling immune responses. 00:11 But they are potentially very dangerous molecules if they are produced in excessive quantities. 00:17 And this can happen in pathological situations where the cytokines are produced inappropriately and can cause pathology. 00:26 There is therefore a need to develop therapeutic agents that can block the activity of cytokines. 00:34 And one way of doing that is to produce monoclonal antibodies. 00:39 These antibodies could be directed against the cytokine themselves, or alternatively, they could be directed against cytokine receptors, and prevent binding of the cytokine to the receptor. 00:52 Of course such antibodies should not trigger the receptor. 00:56 So we need to make sure that such antibodies don’t mimic the effect of cytokine in triggering the receptor. 01:02 But one can produce such antibodies that essentially get in the way of the cytokine binding to the receptor, but do not themselves trigger the receptor. 01:12 And here’s an example of a number of agents that are used therapeutically in the clinic. 01:19 Some of these are antibodies against cytokines, others are antibodies against cytokine receptors. 01:26 I won’t read through this, you can read it perfectly well yourself. 01:29 I’ll just pick out one of these as an example. 01:32 If you look in the middle there you can see anti-TNFα. 01:35 And this is an agent that is used actually in a number of different conditions - rheumatoid arthritis, plaque psoriasis, Crohn disease, ulcerative colitis, ankylosing spondylitis, and so forth. 01:49 In all of these conditions, there is excessive production of TNFα that is contributing to the pathology. 01:56 So these agents, at least in a subset of patients in each of these groups, can be very beneficial in treatment. 02:08 Conversely, sometimes in a pathological situation, there may be either underproduction of a cytokine or it may be that one can beneficially stimulate responses using cytokines. 02:21 So as well as the situation where you may want to block cytokine activity, there are other pathological situations and disease situations where you can use cytokines as therapeutic agents. 02:35 And again, I’m not going to read through this whole list. 02:38 But interferons clearly have anti-viral activity, so can be of potential use in infection. 02:47 Interleukin-2 is an immunostimulatory cytokine, so you can use that to stimulate immune responses and so forth.
The lecture Cell-mediated Immunity: Therapeutic Blocking of Pathological Cytokines and Therapeutic Cytokines by Peter Delves, PhD is from the course Humoral Immunity and Cell-mediated Immunity. It contains the following chapters:
Which of the following cytokines is often targeted in the treatment of rheumatoid arthritis?
Which of the following monoclonal antibodies had or still has applications in diseases such as hepatitis C and hairy cell leukemia?
5 Stars |
|
5 |
4 Stars |
|
0 |
3 Stars |
|
0 |
2 Stars |
|
0 |
1 Star |
|
0 |